Indian pharma companies ranked 19 on 28 in competitiveness index

Indian pharmaceutical companies have ranked at the rear end in the recently conducted 2016 Biopharmaceutical Competitiveness & Investment (BCI) Survey. 

India ranked at number 19 out of 28 countries that were considered in the survey. 

While US took the lead, with its pharma companies ranked as the most competitive with a 89 points score, UK and Switzerland followed after it. 

Catalyst-Phrma said, "though presenting certain policy obstacles, the "Asian Tigers" -- Singapore, South Korea and Taiwan -- and Israel are rated as the most competitive for investment compared to other "newcomer markets" 

The BRIC economies, including India, and remaining APAC place at the rear end of the newcomer markets, it said.

India, along with China, Colombia, Argentina, Turkey, Russia, and Brazil were labelled as trailing markets, based on their overall score, while Saudi Arabia, Mexico and South Africa, the survey found, were "catching their stride".

This is the third edition of the BCI Survey, a global executive opinion survey and index of economies' biomedical investment-attractiveness created by Pugatch Consilium, commissioned by PhRMA. 

According to executives, newcomer markets, including India, are still divided on protecting intellectual property and localising innovation.